CRISPR-enhanced assessment of variants of unknown significance nominates oncology therapeutic targets and drug repositioning opportunities
CRISPR-VUS combines dependency-based rare-variant discovery with evidence-guided prioritisation to nominate candidate drivers, therapeutic targets and drug-repositioning hypotheses to nominate candidate drivers, therapeutic targets and drug-repositioning hypotheses.
A. Savino, Athanasios Oikonomou, Francesca Perrone et al.
· bioRxiv · 0 citations